author_facet Narayan, Ravi
Molenaar, Piet
Cornelissen, Fleur
Wurdinger, Tom
Koster, Jan
Westerman, Bart
Narayan, Ravi
Molenaar, Piet
Cornelissen, Fleur
Wurdinger, Tom
Koster, Jan
Westerman, Bart
author Narayan, Ravi
Molenaar, Piet
Cornelissen, Fleur
Wurdinger, Tom
Koster, Jan
Westerman, Bart
spellingShingle Narayan, Ravi
Molenaar, Piet
Cornelissen, Fleur
Wurdinger, Tom
Koster, Jan
Westerman, Bart
Neuro-Oncology
COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
Cancer Research
Neurology (clinical)
Oncology
author_sort narayan, ravi
spelling Narayan, Ravi Molenaar, Piet Cornelissen, Fleur Wurdinger, Tom Koster, Jan Westerman, Bart 1522-8517 1523-5866 Oxford University Press (OUP) Cancer Research Neurology (clinical) Oncology http://dx.doi.org/10.1093/neuonc/noz175.252 <jats:title>Abstract</jats:title> <jats:p>Personalized cancer treatments using synergistic combinations of drugs is attractive but proves to be highly challenging. The combinatorial nature of such problems results in an enormous parameter space that cannot be resolved by empirical research, i.e. testing all combinations for all molecularly defined tumors. In addition, effective drug synergy is hard to predict. Here we present an approach to map data of drug-response encyclopedias and represent these as a drug atlas. This atlas consists of a framework of chemotherapeutic responses that represents a drug vulnerability landscape of cancer. Based on data from the literature we found that many synergistic drug combinations show distinct inter therapy responses and drug sensitivities. We confirmed this by performing a drug combination screen against glioblastoma where we used 270 combination experiments. From the identified dual therapies we were able to predict and validate a triple drug synergy which was validated in vivo. This new and generalizable strategy opens the door to unforeseen personalized multidrug combination approaches.</jats:p> COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA Neuro-Oncology
doi_str_mv 10.1093/neuonc/noz175.252
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9uZXVvbmMvbm96MTc1LjI1Mg
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9uZXVvbmMvbm96MTc1LjI1Mg
institution DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
imprint Oxford University Press (OUP), 2019
imprint_str_mv Oxford University Press (OUP), 2019
issn 1522-8517
1523-5866
issn_str_mv 1522-8517
1523-5866
language English
mega_collection Oxford University Press (OUP) (CrossRef)
match_str narayan2019comp09acancerdrugatlasenablespredictionofparalleldrugvulnerabilitiesofglioblastoma
publishDateSort 2019
publisher Oxford University Press (OUP)
recordtype ai
record_format ai
series Neuro-Oncology
source_id 49
title COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_unstemmed COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_full COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_fullStr COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_full_unstemmed COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_short COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_sort comp-09. a cancer drug atlas enables prediction of parallel drug vulnerabilities of glioblastoma
topic Cancer Research
Neurology (clinical)
Oncology
url http://dx.doi.org/10.1093/neuonc/noz175.252
publishDate 2019
physical vi62-vi63
description <jats:title>Abstract</jats:title> <jats:p>Personalized cancer treatments using synergistic combinations of drugs is attractive but proves to be highly challenging. The combinatorial nature of such problems results in an enormous parameter space that cannot be resolved by empirical research, i.e. testing all combinations for all molecularly defined tumors. In addition, effective drug synergy is hard to predict. Here we present an approach to map data of drug-response encyclopedias and represent these as a drug atlas. This atlas consists of a framework of chemotherapeutic responses that represents a drug vulnerability landscape of cancer. Based on data from the literature we found that many synergistic drug combinations show distinct inter therapy responses and drug sensitivities. We confirmed this by performing a drug combination screen against glioblastoma where we used 270 combination experiments. From the identified dual therapies we were able to predict and validate a triple drug synergy which was validated in vivo. This new and generalizable strategy opens the door to unforeseen personalized multidrug combination approaches.</jats:p>
container_issue Supplement_6
container_start_page 0
container_title Neuro-Oncology
container_volume 21
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792324976011902982
geogr_code not assigned
last_indexed 2024-03-01T11:58:16.191Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=COMP-09.+A+CANCER+DRUG+ATLAS+ENABLES+PREDICTION+OF+PARALLEL+DRUG+VULNERABILITIES+OF+GLIOBLASTOMA&rft.date=2019-11-11&genre=article&issn=1523-5866&volume=21&issue=Supplement_6&pages=vi62-vi63&jtitle=Neuro-Oncology&atitle=COMP-09.+A+CANCER+DRUG+ATLAS+ENABLES+PREDICTION+OF+PARALLEL+DRUG+VULNERABILITIES+OF+GLIOBLASTOMA&aulast=Westerman&aufirst=Bart&rft_id=info%3Adoi%2F10.1093%2Fneuonc%2Fnoz175.252&rft.language%5B0%5D=eng
SOLR
_version_ 1792324976011902982
author Narayan, Ravi, Molenaar, Piet, Cornelissen, Fleur, Wurdinger, Tom, Koster, Jan, Westerman, Bart
author_facet Narayan, Ravi, Molenaar, Piet, Cornelissen, Fleur, Wurdinger, Tom, Koster, Jan, Westerman, Bart, Narayan, Ravi, Molenaar, Piet, Cornelissen, Fleur, Wurdinger, Tom, Koster, Jan, Westerman, Bart
author_sort narayan, ravi
container_issue Supplement_6
container_start_page 0
container_title Neuro-Oncology
container_volume 21
description <jats:title>Abstract</jats:title> <jats:p>Personalized cancer treatments using synergistic combinations of drugs is attractive but proves to be highly challenging. The combinatorial nature of such problems results in an enormous parameter space that cannot be resolved by empirical research, i.e. testing all combinations for all molecularly defined tumors. In addition, effective drug synergy is hard to predict. Here we present an approach to map data of drug-response encyclopedias and represent these as a drug atlas. This atlas consists of a framework of chemotherapeutic responses that represents a drug vulnerability landscape of cancer. Based on data from the literature we found that many synergistic drug combinations show distinct inter therapy responses and drug sensitivities. We confirmed this by performing a drug combination screen against glioblastoma where we used 270 combination experiments. From the identified dual therapies we were able to predict and validate a triple drug synergy which was validated in vivo. This new and generalizable strategy opens the door to unforeseen personalized multidrug combination approaches.</jats:p>
doi_str_mv 10.1093/neuonc/noz175.252
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9uZXVvbmMvbm96MTc1LjI1Mg
imprint Oxford University Press (OUP), 2019
imprint_str_mv Oxford University Press (OUP), 2019
institution DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161
issn 1522-8517, 1523-5866
issn_str_mv 1522-8517, 1523-5866
language English
last_indexed 2024-03-01T11:58:16.191Z
match_str narayan2019comp09acancerdrugatlasenablespredictionofparalleldrugvulnerabilitiesofglioblastoma
mega_collection Oxford University Press (OUP) (CrossRef)
physical vi62-vi63
publishDate 2019
publishDateSort 2019
publisher Oxford University Press (OUP)
record_format ai
recordtype ai
series Neuro-Oncology
source_id 49
spelling Narayan, Ravi Molenaar, Piet Cornelissen, Fleur Wurdinger, Tom Koster, Jan Westerman, Bart 1522-8517 1523-5866 Oxford University Press (OUP) Cancer Research Neurology (clinical) Oncology http://dx.doi.org/10.1093/neuonc/noz175.252 <jats:title>Abstract</jats:title> <jats:p>Personalized cancer treatments using synergistic combinations of drugs is attractive but proves to be highly challenging. The combinatorial nature of such problems results in an enormous parameter space that cannot be resolved by empirical research, i.e. testing all combinations for all molecularly defined tumors. In addition, effective drug synergy is hard to predict. Here we present an approach to map data of drug-response encyclopedias and represent these as a drug atlas. This atlas consists of a framework of chemotherapeutic responses that represents a drug vulnerability landscape of cancer. Based on data from the literature we found that many synergistic drug combinations show distinct inter therapy responses and drug sensitivities. We confirmed this by performing a drug combination screen against glioblastoma where we used 270 combination experiments. From the identified dual therapies we were able to predict and validate a triple drug synergy which was validated in vivo. This new and generalizable strategy opens the door to unforeseen personalized multidrug combination approaches.</jats:p> COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA Neuro-Oncology
spellingShingle Narayan, Ravi, Molenaar, Piet, Cornelissen, Fleur, Wurdinger, Tom, Koster, Jan, Westerman, Bart, Neuro-Oncology, COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA, Cancer Research, Neurology (clinical), Oncology
title COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_full COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_fullStr COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_full_unstemmed COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_short COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
title_sort comp-09. a cancer drug atlas enables prediction of parallel drug vulnerabilities of glioblastoma
title_unstemmed COMP-09. A CANCER DRUG ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES OF GLIOBLASTOMA
topic Cancer Research, Neurology (clinical), Oncology
url http://dx.doi.org/10.1093/neuonc/noz175.252